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The objective of this study was to evaluate the efficacy and safety of fibrin sealant in patients following total knee
arthroplasty (TKA). A comprehensive literature search of the electronic databases PubMed, MEDLINE, Web of
Science, and Cochrane Library for published randomized controlled trials (RCTs) was undertaken. The evidence base
was critically appraised using a tool from the Cochrane Bone, Joint and Muscle Trauma Group. Eight RCTs involving
641 patients were included. The use of fibrin sealant significantly reduced postoperative drainage (weighted mean
difference (WMD) −346, 95% confidence interval (CI) −496.29 to −197.54, P < 0.00001) and blood transfusions (risk
ratio (RR) 0.47, 95% CI 0.35 to 0.63, P < 0.00001) and led to a significant improvement in the range of motion (WMD
16.59, 95% CI 6.92 to 26.25, P = 0.0008). However, using fibrin sealant did not significantly reduced total blood loss
(WMD −305.25, 95% CI −679.44 to 68.95, P = 0.11). Regarding complications, there were no significant differences in
any adverse events, fever, infection, or hematoma among the study groups. In conclusion, the present meta-analysis
indicates that the use of fibrin sealant was effective and safe as a hemostatic therapy for patients with TKA.
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Total knee arthroplasty (TKA) is a safe and effective
treatment for alleviation of pain and restoration of func-
tion for end-stage knee diseases. However, TKA is asso-
ciated with significant blood loss because of extensive
dissections through bony and fibrotic tissue [1,2]. Blood
loss is a common problem during and after TKA, which
can result in the need for transfusions, postoperative
anemia, and increased costs for health care [3]. In
addition, blood transfusions may also increase the pa-
tient’s risk for postoperative infection [4]. Various tech-
nologies have been employed to minimize the need for
allogeneic blood transfusion. Perioperative strategies in-
clude the use of autologous blood donation and admin-
istration of erythropoietin [5,6]; intraoperative measures
include acute normovolemic hemodilution, hypotensive
anesthesia, intraoperative blood salvage, specialized cautery,
topical hemostatic agents, and pharmacologic agents [7].* Correspondence: Hua_yingqi@163.com; zhdcai@gmail.com
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unless otherwise stated.The use of fibrin sealant (i.e., fibrin glues, fibrin tissue ad-
hesives) could be a promising approach to reduce bleeding
and consequently lead to lower transfusion rates [8]. Fibrin
sealants have been increasingly used as adjunctive surgical
and hemostatic agents for over 20 years [9]. A number of
systematic reviews have examined the efficacy and safety in
cardiac surgery [10], thoracic surgery [11], plastic and re-
constructive surgery [12], and orthopedic surgery settings
[13]. The main components of the sealant are fibrinogen,
factor XIII, thrombin, and antifibrinolytic agents, such as
aprotinin or tranexamic acid. Fibrin sealants achieve
their local hemostatic effects by reproducing the last step
of the coagulation cascade, thereby facilitating formation
of a stable fibrin clot and subsequent hemostasis [14].
To date, several randomized controlled trials (RCTs)
have been done to examine the efficacy of fibrin sealants
for TKA. Results from these trials have indicated that fi-
brin sealants were efficacious and promising agents in
TKA. However, at least two studies found that fibrin
sealants had no effect on drain output or functional re-
covery following TKA [15,16]. The aim of this review is
to evaluate the effectiveness of fibrin sealant treatment
in reducing postoperative blood loss and transfusion for
patients undergoing TKA.td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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Literature search
A systematic search of literature was conducted on PubMed,
Web of Science, MEDLINE, and Cochrane Library data-
bases for relevant articles published until 27 June 2013.
Articles were identified using the following search terms:
‘fibrin sealant’ OR ‘fibrin glues’ OR ‘fibrin tissue adhesives’
AND ‘total knee arthroplasty’ OR ‘total knee replacement’.
The language of the publications was limited to English.
The title and abstract of studies identified in the search
were scanned to exclude any clearly irrelevant studies.
Furthermore, references of identified articles were also
searched manually. A search for unpublished literature
was not performed.
Study selection
To minimize any possible selection bias, the following
criteria were used: (i) the study should be a randomized
controlled trial, (ii) the study should compare the use of
fibrin sealant (fibrin glue, fibrin tissue adhesive) with no
sealant or placebo or standard method of hemostasis or
other hemostatic agents, and (iii) the study should re-
port the clinical outcome of the fibrin sealant in TKA.
We excluded articles of studies on animals, reviews, edi-
torial letters, case reports, poster sessions, or studies with
insufficient data. Firstly, we screened the title and abstract
to see whether they met the inclusion criteria. Then, based
on the initial screening, we scrutinized the full manuscript
of studies that needed further examination.
Study quality
In order to assess the methodological quality of included
studies, two authors used a modification of the generic
evaluation tool used by the Cochrane Bone, Joint and
Muscle Trauma Group [17]. The methodological qualityFigure 1 Process of study selection of randomized controlled trials.of each trial was scored and ranged from 0 to 24. Any
controversy was cross-checked and resolved by a third
author to reach a final consensus.
Date extraction
Two authors extracted independently all relevant data in
the specially predesigned data form; any disagreements
during the extraction process were resolved by consulting
the first author until a final consensus was achieved. For
each trial, the following data were collected: the author
details; year of publication; country in which the study
was performed; study design; general characteristics of pa-
tients, interventions, and control treatment; outcome data;
and definitions of outcomes from studies.
Outcome measures
The primary outcome measures included in this review
were postoperative drainage, total blood loss, blood trans-
fusion, hemoglobin (Hb) drop, range of motion, and
length of hospital stay. Secondary outcome measures were
data about safety, including any adverse events (AEs),
fever, infection, and hematoma.
Statistical analysis
Statistical analysis was performed with Review Manager
version 5.1. For dichotomous data, the risk ratio (RR) and
95% confidence interval (CI) were calculated. Weighted
mean difference (WMD) was used to report continuous
outcomes. Clinical heterogeneity was evaluated by consi-
dering the design of each trial. If clinical heterogeneity did
not exist, the statistical heterogeneity was assessed using
the chi-square test (P < 0.1 indicating significance) and
quantified using the I2 statistic (I2 value > 50% means sig-
nificant heterogeneity). When there was a significant he-
terogeneity across the included trials, a random effects
Table 1 Characteristics of randomized controlled trials included in the meta-analysis
Study Study design Country, year QAS Interventions Number of patients
(FS/control)
Outcomes
Heyse et al. [15] Double-blind, RCT USA, 2013 21 Fibrin sealant 10 ml before tourniquet release 98/100 TBL: FS 1,441 ml vs. control 1,409 ml
Control: no fibrin sealant 24 h postoperative blood drainage: FS 780 ml vs. control 673 ml
48 h postoperative Hb drop: FS 3.47 g/l vs. control 3.84 g/l
Kluba et al. [19] Single-center,
prospective, RCT
Germany, 2012 17 Fibrin sealant 2 ml before closing the wound 12/12 Postoperative blood drainage: FS 475.4 ml vs. control 813.3 ml
Control: no fibrin sealant 8 days postoperative ROM: FS 90.8 vs. control 85.4
Length of hospital stay: FS 12.67 days vs. control 13.67 days
Levy et al. [18] Multicenter,
prospective, RCT
Israel, 1999 18 Fibrin sealant 10–20 ml before closing the wound 29/29 TBL: FS 1,063 ml vs. control 1,768 ml
Control: no fibrin sealant Postoperative blood loss: FS 360 ml vs. control 878 ml
Postoperative Hb drop: FS 25 g/l vs. control 37 g/l
Blood transfusion rate: FS 5 patients vs. control 16 patients
Molloy et al. [20] Prospective, RCT Northern Ireland,
2007
14 Fibrin sealant 6 ml before the prosthesis is inserted,
then 4 ml after placement of the prosthesis
50/50 TBL: FS 1,190 ml vs. control 1,415 ml
Control: no pharmacological intervention Postoperative Hb drop: FS 2.68 g/dl vs. control 3.20 g/dl
Blood transfusion rate: FS 7 patients vs. control 11 patients
Notarnicola et al. [21] Prospective, RCT Italy, 2012 15 Fibrin sealant (5 and 10 ml) before closing the
wound and releasing the tourniquet
30/30/30 3 days postoperative blood drainage: FS (5 ml) 415 ml vs.
FS (10 ml) 228.3 ml vs. control 815 ml
Control: no fibrin sealant Postoperative Hb drop: FS (5 ml) 2.6 mg/dl vs. FS (10 ml)
2.5 mg/dl vs. control 3.7 mg/dl
Blood transfusion rate: FS (5 ml) 10 patients vs. FS (10 ml)
7 patients vs. control 19 patients
7 days postoperative ROM: FS (5 ml) 96.5 vs. FS (10 ml)
98.8 vs. control 75.5
Length of hospital stay: FS (5 ml) 10 days vs. FS (10 ml)
9.2 days vs. control 13.6 days
Sabatini et al. [22] Prospective, RCT Italy, 2012 18 Fibrin sealant 5 ml before the prosthesis is inserted 35/35 3 days postoperative blood drainage: FS 910 ml vs. control 1,250 ml
Control: no fibrin sealant 24 h postoperative Hb drop: FS 2.6 g/dl vs. control 3 g/dl
Blood transfusion rate: FS 5 patients vs. control 15 patients
Skovgaard et al. [16] Double-blind,
prospective, RCT
Denmark, 2013 21 Fibrin sealant 10 ml after the prosthesis is inserted 24/24 24 h postoperative blood drainage: FS 582 ml vs. control 576 ml
Control: placebo 7 days postoperative ROM: FS 88 vs. control 86
Wang et al. [23] Multicenter,
prospective, RCT
USA, 2001 16 Fibrin sealant 10 ml before closing the wound
and releasing the tourniquet
25/28 12 h postoperative blood drainage: FS 184.5 ml vs. control 408.3
24 h postoperative Hb drop: FS 20.1 g/l vs. control 27.3 g/l
Control: no placebo
Blood transfusion rate: FS 9 patients vs. control 14 patients




















Figure 2 Forest plot of combined WMD values for postoperative drainage in TKA.
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present among studies, the fixed effects model was per-
formed. Funnel plot was performed to identify the possi-
bility of publication bias.
Results
Study characteristics and quality assessment
The detailed steps of our literature search are shown in
Figure 1. Briefly, an initial search revealed 324 potentially
relevant studies of which eight RCTs fully met the inclu-
sion criteria [15,16,18-23]. The major characteristics of
the included studies are outlined in Table 1. A total of 641
participants were enrolled in the eight studies, with sam-
ple sizes ranging from 24 to 198 patients. There were 303
patients in the fibrin sealant group and 338 patients in the
control group. In the included studies, participants had
similar demographic data in the two groups. The volume
of fibrin sealant applied to the surgical site varied from 2
to 20 ml, and Notarnicola et al. [21] assessed the efficacy
of two different doses of fibrin sealant (5 and 10 ml) in
TKA. The use of antifibrinolytic agents also varied with
the different agents studied. The total quality assessment
score (QAS) was generally moderate. The mode was 24
(the highest possible score) and the range was 14 to 21,
with only one study scoring > 20.
Meta-analysis of efficacy
Blood loss
Information on blood loss was available for all the stud-
ies included in the meta-analysis. The studies measureFigure 3 Forest plot of combined WMD values for total blood loss inexternal blood loss as the volume contained in the drain,
total blood loss, or a combination of both. Six studies
[16,18,19,21-23] (369 patients) reported postoperative
drainage. Postoperative time until the evaluation of the
drainage was different in each trial: 12 h for the study by
Wang et al., 24 h for the study by Skovgaard et al., 72 h
in the studies by Notarnicola et al. and Sabatini et al.,
and no time given in the study by Levy et al. The general
appraisal of the postoperative drainage indicated that
the use of fibrin sealant significantly reduced postopera-
tive drainage (WMD −346, 95% CI −496.29 to −197.54,
P < 0.00001, Figure 2). There was, however, significant
heterogeneity between studies (P < 0.001, I2 = 94%). Three
studies [15,18,20] (358 patients) reported total blood loss
(TBL). As shown in Figure 3, our meta-analysis showed
that using fibrin sealant did not lead to a significant reduc-
tion of total blood loss (WMD −305.25, 95% CI −679.44
to 68.95, P = 0.11, Figure 3). Again, there was significant
heterogeneity between studies (P = 0.002, I2 = 83%).
Hemoglobin drop
When the result variable was the decrease in Hb level
after the operation, five studies [18,20-23] (401 patients)
were used for the meta-analysis. Postoperative time to
evaluate treatment was 24 h for the Wang et al. study
and Sabatini et al. study and was not given by the studies
of Notarnicola et al., Levy et al., and Molloy et al. The
general estimation for Hb level reduction indicated that
the use of fibrin sealant significantly decreased blood
loss (WMD −0.76, 95% CI −1.02 to −0.51, P < 0.00001,TKA.
Figure 4 Forest plot of combined WMD values for Hb drop in TKA.
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studies (P = 0.23, I2 = 28%).
Blood transfusion
Five studies [18,20-23] (401 patients) were used to per-
form the meta-analysis with the blood transfusion. As
shown in Figure 5, our pooled results showed that the
blood transfusion requirements in the fibrin sealant group
were significantly lower than those in the control group
(RR 0.47, 95% CI 0.35 to 0.63, P < 0.00001, Figure 5).
There was no significant heterogeneity between studies
(P = 0.52, I2 = 0%).
Range of motion
Two studies [19,21] (144 patients) were used to perform
the meta-analysis with the range of motion. Postopera-
tive time to evaluate treatment was 8 days for the Kluba
et al. study and 17 days for the Notarnicola et al. study.
As shown in Figure 6, our pooled results showed that
the range of motion in the fibrin sealant group was sig-
nificantly better than that in the control group (WMD
16.59, 95% CI 6.92 to 26.25, P = 0.008, Figure 6). There
was significant heterogeneity between studies (P < 0.001,
I2 = 94%).Figure 5 Forest plot of combined RR values for the number of patienLength of hospital stay
Two studies [19,21] (144 patients) reported the length of
hospital stay, and the meta-analysis results showed that
the use of fibrin sealant was significantly associated
with a reduced hospital stay (WMD −3.66, 95% CI −4.89
to −2.43, P < 0.00001, Figure 7). There was significant het-
erogeneity between studies (P = 0.12, I2 = 53%).
Meta-analysis of safety
Results concerning safety are demonstrated in Table 2.
Data regarding occurrence of any adverse events, fever,
infection, and hematoma are extracted from each study.
The results of the meta-analysis showed that the inci-
dences of adverse events, fever, infection, and hematoma
were similar between the two groups. However, the num-
ber of events was too small to draw firm conclusions. We
did not evaluate the risk of deep venous thrombosis be-
cause of insufficient data for pooling.
Discussion
The benefit of using fibrin sealant has been demonstrated
in several clinical studies, most of which show reduced
blood loss, lower transfusion rate, improved range of mo-
tion, and shorter hospital stay. Similarly, the results ofts requiring blood transfusions in TKA.
Figure 6 Forest plot of combined WMD values for range of motion in TKA.
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benefit in using fibrin sealant in patients following TKA
as well. However, these results must be interpreted with
caution because of the significant heterogeneity in trial
findings.
Most of the observed heterogeneity seemed to be from
clinical practice or trial methodology. First, for time of
evaluation, the outcome measures were different. To
avoid a possible bias, the time of evaluation period was
considered ‘short term’ (ranging 12 to 72 h). For ex-
ample, drainage output at 24 h in the Skovgaard et al.
study was around 580 ml, as compared to 878 ml in the
Levy et al. study [18] and 408 ml in the Wang et al.
study [23] after 12 h. Besides, the amount of fibrin seal-
ant used may influence the blood drainage: Levy et al.
[18] used 10–20 ml, Kluba et al. [19] used 2 ml, and
Notarnicola et al. [21] assessed the efficacy of two differ-
ent doses (5 and 10 ml). However, the dose of fibrin seal-
ant did not appear to have any bearing on the results.
Furthermore, tourniquet time and tourniquet pressure
should be kept short and low, and differences in these
trials may also influence the outcome. Also, fibrin seal-
ant may contain tranexamic acid, which has been dem-
onstrated to be effective on its own in reducing blood
loss. Finally, the control group in this review consisted
of a variety of interventions including no fibrin sealant,
placebo, and standard method of treatments, resulting in
clinical and methodological heterogeneity. Subgroup
analysis by the evaluation time and dose of fibrin sealant
was constrained by the small number of trials.
Bleeding remains an ongoing concern after TKA. Fi-
brin sealants are topically applied hemostatic agents thatFigure 7 Forest plot of combined WMD values for length of hospitalreduce the time required to achieve hemostasis as well
as the volume of blood loss. Wang et al. [23] found that
there was a statistically significant reduction in blood
loss 12 h postoperatively (184.5 ml in the fibrin sealant
group vs. 408.3 ml in the control group), as well as a
minor Hb reduction on the first postoperative day as
compared with baseline (14.9% vs. 20.7%). However, in
the Heyse et al. study [15], it was found that the use of
topical fibrinogen did not lead to a relevant reduction in
blood loss or transfusions in primary TKA. They consid-
ered that suction drainage may have affected the impact
of topically applied fibrinogen. Molloy et al. [20] reported
that the main cause was they did not spray the prepared
bone surfaces before placement of the cementless compo-
nents. Additionally, the amount of blood loss after TKA is
often underestimated because measuring blood loss is a
complex science in a controlled clinical trial environment.
This may be one reason why the use of fibrin sealant did
not significantly reduce total blood loss compared with
the control group.
In the study by Kluba et al. [19], fibrin sealant patients
showed a slightly better range of motion and functional
knee recovery compared with the control group of pa-
tients with a maximum flexion 8 days after surgery, but
the difference missed statistical significance (P = 0.052).
Similarly, Heyse et al. [15] had shown that there was no
difference between the two groups at 6 weeks follow-up.
However, in the Notarnicola et al. [21] study, functional
recovery was quicker in patients administered the fibrin
sealant. They believed that fibrin sealant use allowed
an immediate control of bleeding, which may have a
beneficial effect on the achievement of early and betterstay in TKA.
Table 2 Summary of adverse events in randomized controlled trials included in the meta-analysis






Statistical method Effect estimate P value
Any adverse
events
3 61/164 50/164 0.007, 80% Risk ratio (M-H, fixed, 95% CI) 1.21 (0.63, 2.31) 0.57
Fever 3 34/164 32/164 0.94, 0% Risk ratio (M-H, fixed, 95% CI) 1.06 (0.79, 1.44) 0.69
Infection 2 3/129 2/129 0.71, 0% Risk ratio (M-H, fixed, 95% CI) 1.50 (0.26, 8.72) 0.65
Hematoma 2 3/60 10/63 0.90, 0% Risk ratio (M-H, fixed, 95% CI) 0.31 (0.09, 1.08) 0.07
M-H Mantel-Haenszel.
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the difference was not significant between the groups.
However, it is important to state that the range of motion
include only a few trials (less than 2) and have a small sam-
ple size (less than 144). Further randomized prospective
studies will be needed to clarify the relationship between
the use of fibrin sealant in TKA and the functional results.
Postoperative thromboembolism is one of the most
serious and potentially fatal complications after TKA
[24]. The Italian Agency of Drugs (AIFA) had informed
that the use of a spray device to apply fibrin sealant can
produce massive embolism. They recommend to use a
spray device with pressure of less than 2.0–2.5 bar, to
apply fibrin sealant (Quixil, a commercial fibrin sealant;
OMRIX Biopharmaceuticals, Ltd., Kiryat-Ono, Israel)
from a minimal distance of 10–15 cm, and to monitor pa-
tient spray application. Sabatini et al. [22] did not find any
clinical signs of pulmonary embolism with application of
these recommendations. Levy et al. [18] believed that the
use of fibrin sealant may allow the use of full-dose pre-
operative thromboprophylaxis with low molecular weight
heparin, thereby reducing the risk of deep vein thrombosis
without increasing the risk of postoperative bleeding in
patients following TKA. Additionally, our pooled results
showed that there were no significant differences on com-
plications in the fibrin sealant compared with the control
group, including AEs, infection, fever, and hematoma.
The cost of fibrin sealant also warrants discussion.
The beneficial effects of using fibrin sealant are associ-
ated with reduced blood loss and decreased rates of allo-
geneic red blood cell (RBC) transfusion [13]. In the study
by Molloy et al. [20], the cost of the pharmaceutical inter-
vention involved in the topical fibrin group was £380,
which did not justify its additional cost. However, in the
trial by Kluba et al. [19], results showed that in daily clin-
ical practice, a routine application of fibrin sealant adds
costs to TKA treatment without reducing the number of
transfused RBC. Steuten et al. [25] performed a simple
cost model to compare the cost of using a commercial fi-
brin sealant. Their conclusion is that whether using fibrin
sealant is cost saving strongly depends on the amount
used, the achieved reduction in hospital length of stay,
and the price of fibrin sealant.There are several limitations to our meta-analysis.
First, we only included the study in English, and some
relevant studies might not be included in the review.
The few numbers of studies included in our analysis
would limit the statistical power. Additionally, most of
the studies did not report the results of all outcomes se-
lected; each outcome measure was assessed in a variable
number of studies and in different studies which could
make comparison difficult between different domains.
Furthermore, the methodological quality of the trials
was poor, with only two trials judged to be double-blind.
Nevertheless, our meta-analysis has several strengths.
First, this review combined relevant literature published
up to June 2013, with eight RCTs included in our meta-
analysis. Furthermore, the present study is the first sys-
tematic review assessing the efficacy and safety of fibrin
sealant treatment in patients with TKA.
Conclusions
This meta-analysis investigated the efficacy and safety of
fibrin sealant in terms of blood loss, Hb level, range of
motion, length of hospital stay, and complications. Based
on our findings, the use of fibrin sealant was effective
and safe as a hemostatic therapy for patients with TKA.
Given the limitation in this study, fibrin sealant treat-
ment should be carefully considered for each patient.
Further well-designed and large-scale clinical trials and
systemic reviews are required to confirm these findings.
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